Authors

Foundation Fighting Blindness releases 4-year RUSH2A data to public

RUSH2A is an ongoing natural history study for patients with mutations in the USH2A gene causing Usher syndrome type 2A or nonsyndromic retinitis pigmentosa (RP).

FDA approvals in 2025: What changed and why it matters for ophthalmologists

An in-depth look at the FDA approvals and clinical milestones that defined 2025 and how they are poised to influence practice patterns moving into 2026.

Beyond the surface: Tackling complex dry eye cases

Ophthalmologists weigh in on evolving diagnostic tools, emerging therapies, and practical approaches for managing today’s most challenging ocular-surface cases.

Inflammasome Therapeutics completes phase 2 trial enrollment for K8 in GA

K8 is a member of a new class of inflammasome-inhibiting drugs called kamuvudines.

Neurotrophic keratitis outcomes improve with early, stage-based care

A study from a tertiary eye hospital suggests that effective keratitis management may have the potential to restore vision.

SAHARA trial demonstrates sustained TearCare benefits for evaporative DED

New findings confirm TearCare's long-term effectiveness for dry eye disease, showing significant patient improvements with minimal treatments over 2 years.

AAO 2025: Clinical outcomes of early vs delayed pegcetacoplan treatment in GA

Innovation Series: Putting the buzz of large language models in ophthalmology into perspective with Robert T. Chang, MD

Robert T. Chang, MD, from Stanford University discusses how large language models are transforming ophthalmology by enhancing patient communication, documentation, and education, while also addressing ethical considerations and potential future applications in glaucoma care.

Envision Summit 2025: Eradicating TRD

At the Envision Summit 2025 in San Juan, Puerto Rico, Kristen Nwanyanwu, MD, MBA, MHS, joined by her children, discussed her talk on eradicating TRD and the family-friendly environment of the conference.

AAO 2025: The rise of presbyopia research

Hipsley shares insights into ocular biomechanics and dynamic range of focus, that can help the field to work toward vision restoration and increase eye health.

EyePoint receives second consecutive positive recommendation from DSMC

EyePoint Pharmaceuticals' DURAVYU trials for wet AMD receive positive DSMC review, highlighting safety and potential for improved patient outcomes.

EnVision Summit 2025: Complications in glaucoma surgery

At the EnVision Summit 2025 in San Juan, Puerto Rico, Tania Tai, Lucy Shen, and Shivani Kamat all gave insight into complications they have seen while performing glaucoma surgery.